The Company reported a net loss of approximately $8.4 million, or $0.25 per share, for the three months ended September 30, ...

A psychiatrist, Dr Yennusom Maalug, has cautioned that, untreated bipolar or mood disorders could lead to serious mental and ...

One in five adults said they experienced any symptoms of anxiety or depression in a 2 ... trial testing its investigational ...

Researchers are using a groundbreaking technique to visualize a crucial molecule involved in neurotransmission in patients ...

Presentations include results from two pivotal studies (Studies 501 and 502) evaluating lumateperone as an adjunctive therapy to antidepressants ...

Insurer access challenges likely lie ahead for the novel schizophrenia drug Cobenfy, given its considerably higher price than ...

Discover how metabolic ketogenic therapy differs from the popular diet trend and its potential benefits for bipolar disorder.

Intra-Cellular Therapies' lumateperone shows significant efficacy in reducing schizophrenia relapse rates, with a 63% risk ...

Intra-Cellular Therapies’ atypical antipsychotic medication Caplyta has been on a roll, delivering fast commercial growth and coming up triumphant in yet another late-stage trial. | Intra-Cellular ...

Even though psychiatric disorders such as schizophrenia, bipolar disorder, and autism spectrum disorder (ASD) are quite ...

Studying synapses in live human brains is crucial for understanding many psychiatric disorders. Now, using positron emission ...